N-acetyl-l-tryptophan delays disease onset and extends survival in an amyotrophic lateral sclerosis transgenic mouse model

Neurobiology of Disease

Volumn 80, Issue , 2015, Pages 93-103

  Li, Wei ^a   Fotinos, Anastasios ^a   Wu, Qiaofeng ^a   Chen, Yanchun ^a,b   Zhu, Yongjin ^a   Baranov, Sergei ^a   Tu, Yanyang ^a   Zhou, Edward W ^a   Sinha, Bharati ^a   Kristal, Bruce S ^a   Wang, Xin ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Amyotrophic lateral sclerosis; Inflammation; Mitochondrial death pathway; MSOD1G93A mice; N acetyl l tryptophan; Neurokinin 1 receptor; Neuroprotection

Indexed keywords

N ACETYLTRYPTOPHAN; NEUROKININ 1 RECEPTOR; N-ACETYLTRYPTOPHAN; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE; TRYPTOPHAN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; COORDINATION; DOWN REGULATION; FEMALE; INFLAMMATION; MALE; MITOCHONDRION; MORTALITY; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TRANSGENIC MOUSE; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; DRUG EFFECTS; GENETICS; GLIA; METABOLISM; MOTONEURON; PATHOLOGY; SPINAL CORD;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; APOPTOSIS; MALE; MICE; MICE, TRANSGENIC; MITOCHONDRIA; MOTOR NEURONS; NEUROGLIA; RECEPTORS, NEUROKININ-1; SPINAL CORD; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS; TRYPTOPHAN;

EID: 84938813964     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.05.002     Document Type: Article

References (80)

1. Baranov S.V., Stavrovskaya I.G., Brown A.M., Tyryshkin A.M., Kristal B.S. Kinetic model for Ca2+-induced permeability transition in energized liver mitochondria discriminates between inhibitor mechanisms. J. Biol. Chem. 2008, 283:665-676.
2. Barker R. Substance P and neurodegenerative disorders. A speculative review. Neuropeptides 1991, 20:73-78.
3. Blasco H., Corcia P., Pradat P.F., Bocca C., Gordon P.H., Veyrat-Durebex C., Mavel S., Nadal-Desbarats L., Moreau C., Devos D., Andres C.R., Emond P. Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry. J. Proteome Res. 2013, 12:3746-3754.
4. Boot J.D., de Haas S., Tarasevych S., Roy C., Wang L., Amin D., Cohen J., Sterk P.J., Miller B., Paccaly A., Burggraaf J., Cohen A.F., Diamant Z. Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am. J. Respir. Crit. Care Med. 2007, 175:450-457.
5. Brahmachari S., Fung Y.K., Pahan K. Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J. Neurosci. 2006, 26:4930-4939.
6. Caioli S., Curcio L., Pieri M., Antonini A., Marolda R., Severini C., Zona C. Substance P receptor activation induces downregulation of the AMPA receptor functionality in cortical neurons from a genetic model of Amyotrophic Lateral Sclerosis. Neurobiol. Dis. 2011, 44:92-101.
7. Chen Y., Guan Y., Liu H., Wu X., Yu L., Wang S., Zhao C., Du H., Wang X. Activation of the Wnt/beta-catenin signaling pathway is associated with glial proliferation in the adult spinal cord of ALS transgenic mice. Biochem. Biophys. Res. Commun. 2012, 420:397-403.
8. Chen Y., Guan Y., Zhang Z., Liu H., Wang S., Yu L., Wu X., Wang X. Wnt signaling pathway is involved in the pathogenesis of amyotrophic lateral sclerosis in adult transgenic mice. Neurol. Res. 2012, 34:390-399.
9. Costa S.K., Starr A., Hyslop S., Gilmore D., Brain S.D. How important are NK1 receptors for influencing microvascular inflammation and itch in the skin? Studies using Phoneutria nigriventer venom. Vasc. Pharmacol. 2006, 45:209-214.
10. Crompton M., Virji S., Doyle V., Johnson N., Ward J.M. The mitochondrial permeability transition pore. Biochem. Soc. Symp. 1999, 66:167-179.
11. Cui Y., Masaki K., Yamasaki R., Imamura S., Suzuki S.O., Hayashi S., Sato S., Nagara Y., Kawamura M.F., Kira J. Extensive dysregulations of oligodendrocytic and astrocytic connexins are associated with disease progression in an amyotrophic lateral sclerosis mouse model. J. Neuroinflammation 2014, 11:42.
12. De Swert K.O., Bracke K.R., Demoor T., Brusselle G.G., Joos G.F. Role of the tachykinin NK1 receptor in a murine model of cigarette smoke-induced pulmonary inflammation. Respir. Res. 2009, 10:37.
13. Dietl M.M., Sanchez M., Probst A., Palacios J.M. Substance P receptors in the human spinal cord: decrease in amyotrophic lateral sclerosis. Brain Res. 1989, 483:39-49.
14. Donkin J.J., Nimmo A.J., Cernak I., Blumbergs P.C., Vink R. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J. Cereb. Blood Flow Metab. 2009, 29:1388-1398.
15. Donkin J.J., Cernak I., Blumbergs P.C., Vink R. A substance P antagonist reduces axonal injury and improves neurologic outcome when administered up to 12hours after traumatic brain injury. J. Neurotrauma 2011, 28:217-224.
16. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 2002, 52:771-778.
17. Etogo A.O., Nunez J., Lin C.Y., Toliver-Kinsky T.E., Sherwood E.R. NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis. J. Immunol. 2008, 180:6334-6345.
18. Fujita Y., Anzai M., Inui M., Nishimoto T., Inoue G. Utilization of N-acetyl-l-tryptophan given intravenously to unrestrained adult rats. J. Nutr. Sci. Vitaminol. 1980, 26:381-388.
19. Gill A., Kidd J., Vieira F., Thompson K., Perrin S. No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS One 2009, 4:e6489.
20. Guan Y.J., Wang X., Wang H.Y., Kawagishi K., Ryu H., Huo C.F., Shimony E.M., Kristal B.S., Kuhn H.G., Friedlander R.M. Increased stem cell proliferation in the spinal cord of adult amyotrophic lateral sclerosis transgenic mice. J. Neurochem. 2007, 102:1125-1138.
21. Guegan C., Vila M., Rosoklija G., Hays A.P., Przedborski S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J. Neurosci. 2001, 21:6569-6576.
22. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
23. Harford-Wright E., Lewis K.M., Vink R., Ghabriel M.N. Evaluating the role of substance P in the growth of brain tumors. Neuroscience 2014, 261:85-94.
24. Heuther G., Hajak G., Reimer A., Poeggeler B., Blomer M., Rodenbeck A., Ruther E. The metabolic fate of infused l-tryptophan in men: possible clinical implications of the accumulation of circulating tryptophan and tryptophan metabolites. Psychopharmacology 1992, 109:422-432.
25. Holden J.E., Pizzi J.A., Jeong Y. An NK1 receptor antagonist microinjected into the periaqueductal gray blocks lateral hypothalamic-induced antinociception in rats. Neurosci. Lett. 2009, 453:115-119.
26. Jaarsma D. Swelling and vacuolisation of mitochondria in transgenic SOD1-ALS mice: a consequence of supranormal SOD1 expression?. Mitochondrion 2006, 6:48-49. (author reply 50-41).
27. Kaneb H.M., Sharp P.S., Rahmani-Kondori N., Wells D.J. Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One 2011, 6:e24189.
28. Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2005, 191:331-336.
29. Kiaei M., Kipiani K., Petri S., Chen J., Calingasan N.Y., Beal M.F. Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener Dis 2005, 2:246-254.
30. Kiaei M., Petri S., Kipiani K., Gardian G., Choi D.K., Chen J., Calingasan N.Y., Schafer P., Muller G.W., Stewart C., Hensley K., Beal M.F. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2006, 26:2467-2473.
31. Levine J.B., Kong J., Nadler M., Xu Z. Astrocytes interact intimately with degenerating motor neurons in mouse amyotrophic lateral sclerosis (ALS). Glia 1999, 28:215-224.
32. Lewis K.M., Harford-Wright E., Vink R., Ghabriel M.N. NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer. Anti-Cancer Drugs 2013, 24:344-354.
33. Li M., Ona V.O., Chen M., Kaul M., Tenneti L., Zhang X., Stieg P.E., Lipton S.A., Friedlander R.M. Functional role and therapeutic implications of neuronal caspase-1 and -3 in a mouse model of traumatic spinal cord injury. Neuroscience 2000, 99:333-342.
34. Li M., Ona V.O., Guegan C., Chen M., Jackson-Lewis V., Andrews L.J., Olszewski A.J., Stieg P.E., Lee J.P., Przedborski S., Friedlander R.M. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000, 288:335-339.
35. Li X., Guan Y., Chen Y., Zhang C., Shi C., Zhou F., Yu L., Juan J., Wang X. Expression of Wnt5a and its receptor Fzd2 is changed in the spinal cord of adult amyotrophic lateral sclerosis transgenic mice. Int. J. Clin. Exp. Pathol. 2013, 6:1245-1260.
36. Makino A., Sakai A., Ito H., Suzuki H. Involvement of tachykinins and NK1 receptor in the joint inflammation with collagen type II-specific monoclonal antibody-induced arthritis in mice. J. Nippon Med. Sch. 2012, 79:129-138.
37. Mantyh P.W. Neurobiology of substance P and the NK1 receptor. J. Clin. Psychiatry 2002, 63(Suppl. 11):6-10.
38. Martin L.J., Liu Z., Chen K., Price A.C., Pan Y., Swaby J.A., Golden W.C. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J. Comp. Neurol. 2007, 500:20-46.
39. McCombe P.A., Henderson R.D. The role of immune and inflammatory mechanisms in ALS. Curr. Mol. Med. 2011, 11:246-254.
40. Munoz M., Rosso M., Perez A., Covenas R., Rosso R., Zamarriego C., Piruat J.I. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 2005, 39:427-432.
41. Munoz M., Gonzalez-Ortega A., Rosso M., Robles-Frias M.J., Carranza A., Salinas-Martin M.V., Covenas R. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides 2012, 38:318-325.
42. Nagao M., Kato S., Miyazaki Y., Hayashi H. Trace of cell death of spinal motoneutron of ALS: about the role of Smac/DIABLO. Annual Report of the Research Committee on the Neurodegenerative Diseases of the Ministry of Health 2003, 25-26. Labour and Welfare, Japan.
43. Oh Y.K., Shin K.S., Kang S.J. AIF translocates to the nucleus in the spinal motor neurons in a mouse model of ALS. Neurosci. Lett. 2006, 406:205-210.
44. Pandya R.S., Mao L.L., Zhou E.W., Brower R., Zhu Z., Zhu Y., Wang X. Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy. Cent. Nerv. Syst. Agents. Med. Chem. 2012, 12:15-27.
45. Pandya R.S., Zhu H., Li W., Bowser R., Friedlander R.M., Wang X. Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 2013, 70:4729-4745.
46. Pasinelli P., Houseweart M.K., Brown R.H., Cleveland D.W. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13901-13906.
47. Quartara L., Altamura M. Tachykinin receptors antagonists: from research to clinic. Curr. Drug Targets 2006, 7:975-992.
48. Quartara L., Maggi C.A. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides 1998, 32:1-49.
49. Rasola A., Bernardi P. Mitochondrial permeability transition in Ca(2+)-dependent apoptosis and necrosis. Cell Calcium 2011, 50:222-233.
50. Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown R.H., Ferrante R.J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 2005, 93:1087-1098.
51. Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur. J. Pharmacol. 1999, 375:51-60.
52. Schiffer D., Cordera S., Cavalla P., Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 1996, 139:27-33. (Suppl.).
53. Schutz B., Reimann J., Dumitrescu-Ozimek L., Kappes-Horn K., Landreth G.E., Schurmann B., Zimmer A., Heneka M.T. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 2005, 25:7805-7812.
54. Shoemaker J.L., Seely K.A., Reed R.L., Crow J.P., Prather P.L. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. 2007, 101:87-98.
55. Singh A.S., Caplan A., Corcoran K.E., Fernandez J.S., Preziosi M., Rameshwar P. Oncogenic and metastatic properties of preprotachykinin-I and neurokinin-1 genes. Vasc. Pharmacol. 2006, 45:235-242.
56. Stavrovskaya I.G., Narayanan M.V., Zhang W., Krasnikov B.F., Heemskerk J., Young S.S., Blass J.P., Brown A.M., Beal M.F., Friedlander R.M., Kristal B.S. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J. Exp. Med. 2004, 200:211-222.
57. Sunyach C., Michaud M., Arnoux T., Bernard-Marissal N., Aebischer J., Latyszenok V., Gouarne C., Raoul C., Pruss R.M., Bordet T., Pettmann B. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology 2012, 62:2346-2352.
58. Tanaka H., Shimazaki H., Kimura M., Izuta H., Tsuruma K., Shimazawa M., Hara H. Apoptosis-inducing factor and cyclophilin a cotranslocate to the motor neuronal nuclei in amyotrophic lateral sclerosis model mice. CNS Neurosci. Ther. 2010, 17:294-304.
59. Tao K., Wang H.T., Chen B., Wang B.T., Li Z.Y., Zhu X.X., Tang C.W., Hu D.H. Effect of nonpeptide NK1 receptor antagonist L-703,606 on the edema formation in rats at early stage after deep partial-thickness skin scalding. Asian Pac. J. Trop. Med. 2013, 6:387-394.
60. Thornton E., Vink R. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. PLoS One 2012, 7:e34138.
61. Thornton E., Hassall M.M., Corrigan F., Vink R. The NK1 receptor antagonist N-acetyl-l-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model. Parkinsonism Relat. Disord. 2014, 20:508-513.
62. Tokuda E., Ono S., Ishige K., Watanabe S., Okawa E., Ito Y., Suzuki T. Dysequilibrium between caspases and their inhibitors in a mouse model for amyotrophic lateral sclerosis. Brain Res. 2007, 1148:234-242.
63. Tumati S., Largent-Milnes T.M., Keresztes A.I., Yamamoto T., Vanderah T.W., Roeske W.R., Hruby V.J., Varga E.V. Tachykinin NK(1) receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation. Eur. J. Pharmacol. 2012, 684:64-70.
64. Turner R.J., Blumbergs P.C., Vink R. A substance P antagonist improves outcome following reversible middle cerebral artery occlusion in rats. J. Cereb. Blood Flow Metab. 2005, S32.
65. Vinet-Oliphant H., Alvarez X., Buza E., Borda J.T., Mohan M., Aye P.P., Tuluc F., Douglas S.D., Lackner A.A. Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS. Am. J. Pathol. 2010, 177:1286-1297.
66. Vink R., Donkin J.J., Cruz M.I., Nimmo A.J., Cernak I. A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats. J. Am. Coll. Nutr. 2004, 23:538S-540S.
67. Vukosavic S., Dubois-Dauphin M., Romero N., Przedborski S. Bax and Bcl-2 interaction in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 1999, 73:2460-2468.
68. Wang H., Guan Y., Wang X., Smith K., Cormier K., Zhu S., Stavrovskaya I.G., Huo C., Ferrante R.J., Kristal B.S., Friedlander R.M. Nortriptyline delays disease onset in models of chronic neurodegeneration. Eur. J. Neurosci. 2007, 26:633-641.
69. Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS. Neurosci. Ther. 2009, 15:345-357.
70. Wang X., Zhu S., Pei Z., Drozda M., Stavrovskaya I.G., Del Signore S.J., Cormier K., Shimony E.M., Wang H., Ferrante R.J., Kristal B.S., Friedlander R.M. Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J. Neurosci. 2008, 28:9473-9485.
71. Weisshaar C.L., Winkelstein B.A. Ablating spinal NK1-bearing neurons eliminates the development of pain and reduces spinal neuronal hyperexcitability and inflammation from mechanical joint injury in the rat. J. Pain 2014, 15:378-386.
72. West M., Mhatre M., Ceballos A., Floyd R.A., Grammas P., Gabbita S.P., Hamdheydari L., Mai T., Mou S., Pye Q.N., Stewart C., West S., Williamson K.S., Zemlan F., Hensley K. The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J. Neurochem. 2004, 91:133-143.
73. Whitehouse P.J., Wamsley J.K., Zarbin M.A., Price D.L., Tourtellotte W.W., Kuhar M.J. Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors. Ann. Neurol. 1983, 14:8-16.
74. Wu A.S., Kiaei M., Aguirre N., Crow J.P., Calingasan N.Y., Browne S.E., Beal M.F. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurochem. 2003, 85:142-150.
75. Yu L., Guan Y., Wu X., Chen Y., Liu Z., Du H., Wang X. Wnt signaling is altered by spinal cord neuronal dysfunction in amyotrophic lateral sclerosis transgenic mice. Neurochem. Res. 2013, 38:1904-1913.
76. Zhang Y., Cook A., Kim J., Baranov S.V., Jiang J., Smith K., Cormier K., Bennett E., Browser R.P., Day A.L., Carlisle D.L., Ferrante R.J., Wang X., Friedlander R.M. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2013, 55:26-35.
77. Zhou F., Guan Y., Chen Y., Zhang C., Yu L., Gao H., Du H., Liu B., Wang X. miRNA-9 expression is upregulated in the spinal cord of G93A-SOD1 transgenic mice. Int. J. Clin. Exp. Pathol. 2013, 6:1826-1838.
78. Zhou H., Wang J., Jiang J., Stavrovskaya I., Li M., Li W., Wu Q., Zhang X.M., Luo C.L., Zhou S., Sirianni A.C., Sarkar S., Kristal B., Friedlander R.M., Wang X. N-acetyl-serotonin offers neuroprotection through inhibiting mitochondrial death pathways and autophagic activation in experimental models of ischemic injury. J. Neurosci. 2014, 34:2967-2978.
79. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu D.C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417:74-78.
80. Zhu Y., Fotinos A., Mao L.L., Atassi N., Zhou E.W., Ahmad S., Guan Y., Berry J.D., Cudkowicz M.E., Wang X. Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discov. Today 2015, 20:65-75.